

**AKUMS**  
**DRUGS & PHARMACEUTICALS LTD.**



Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I,  
(Adjoining CBSE Office) Delhi - 110083 (INDIA).

www.akums.in

akumsho@akums.net

+91-11-69041000

CIN: L24239DL2004PLC125888

+91-11-27023256

Ref: Akums/Exchange/2025-26/80

February 13, 2026

**To,**  
**The Listing Department**  
**National Stock Exchange of India Ltd**  
**Exchange Plaza, C-1, Block G,**  
**Bandra Kurla Complex,**  
**Bandra (E), Mumbai - 400 051**

**To,**  
**The Listing Department**  
**BSE Limited**  
**Rotunda Building, Phiroze Jeejeebhoy**  
**Towers, Dalal Street, Fort, Mumbai -**  
**400 001**

**Symbol: AKUMS**

**Scrip Code: 544222**

**Sub: Press Release**

Respected Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of press release is enclosed herewith.

This is for your kind information and record.

Thanking You

**For Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik  
Company Secretary & Compliance Officer

Encl: as above

Registered Office

304, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA).

+91-11-47511000

+91-11-27023256

## **Akums delivers strong Q3 FY26 performance with 14.8% revenue growth and 21% Adj EBITDA growth**

New Delhi, February 13 2026:

Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the third quarter of FY26.

Q3 FY 26 saw strong performance across its key business segments. CDMO saw a revenue growth of over 16% spurred on by double digit increase in volumes. The international branded formulation segment more than doubled sequentially led by demand recovery across its key markets.

Adj EBITDA increased 21% YoY to Rs 147 cr as better capacity utilization along with a steady ramp up in the newer facilities led to margin improvement. Tighter control over overheads and portfolio rationalization helped mitigate losses in the API and Trade generics segment as well.

Our march towards becoming a global manufacturing company continued unabated with the Company receiving European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities. The certification includes the renewal of EU GMP approval for our Oral Solids’ plant and the grant of EU GMP certification for our Oral Liquids Plant. Akums also received its first approval from the UK MHRA for Rivaroxaban tablets

Commenting on the development, Mr. Sandeep Jain, Managing Director, stated, “The EU GMP certifications reflect the strength of our compliant infrastructure, robust quality systems, and the expertise of our skilled teams. We remain focused on disciplined growth while steadily strengthening our presence in regulated markets.”

Mr. Sanjeev Jain, Managing Director, added, “Our continued focus on operational excellence and disciplined growth is aligned with our long-term global vision, enabling us to expand responsibly across regulated markets and strengthen partnerships worldwide.”

Highlights are as under:

(Rs in Crores)

<b>Particulars</b>	<b>Q3FY 26</b>	<b>Q3FY 25</b>	<b>YoY change</b>	<b>Q2FY 26</b>	<b>9MFY26</b>	<b>9MFY25</b>	<b>YoY change</b>
Revenue	1,160	1,010	14.8%	1,018	3,201	3,063	4.5%
Adj EBITDA	147	121	21.0%	94	370	367	1.0%
Adj EBITDA Margin	12.7%	12.0%		9.3%	11.6%	12.0%	
Adj PAT	86	66	29.5%	43	193	190	1.6%
Adj PAT Margin	7.2%	6.5%		4.1%	5.9%	6.1%	

## **Definitions**

- Adjusted EBITDA has been calculated as the sum of profit/ (loss) for the quarter, tax expenses, finance costs, depreciation and amortization expense, fair value changes to financial instruments, and exceptional items minus other income.
- Adjusted PAT is calculated as the profit for the quarter plus fair value changes to financial instruments less tax deferred tax created on brought forward losses. It excludes the one-time impact of new Labour codes.
- CDMO: Contract Development and Manufacturing Operations
- API: Active Pharmaceutical Ingredients

**For further information, please contact:**

**IR Desk**

Akums Drugs and Pharmaceuticals Ltd

[investors@akums.net](mailto:investors@akums.net)/[ankit.jain@akums.net](mailto:ankit.jain@akums.net)